NEUROPRO
DEAD

Serial Number

85872878

Owner

Neurodyn Inc.

Filing Date

Mar 11, 2013

Add to watchlist:

No watchlists yet
View on USPTO

NEUROPRO Trademark

Serial Number: 85872878

NEUROPRO is a trademark filed by Neurodyn Inc. on March 11, 2013. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Neurodyn Inc. (2 trademarks)

1260 - 1188 West Georgia St.
Vancouver, BC V6E4A2 , CA

Entity Type: 03

Trademark Details

Filing Date

March 11, 2013

Registration Date

Not Registered

Goods & Services

Herbal supplements containing ginseng and ginsenocides, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng and omega-3 fatty acids, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginsenocides, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginsenocides and omega-3 fatty acids, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng extract, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; Nutritional supplements containing ginseng extract and omega-3 fatty acids, in tablet, capsule, gel, powder or liquid form, for both the prevention and treatment of neurodegenerative diseases, namely, Parkinson's disease, Alzheimer's disease, and Amyotrophic lateral sclerosis, and the treatment of spinal cord injury, brain injury, promotion and maintenance of healthy neurons, memory, and cognitive function; medical food supplements in powdered, liquid and tablet form for the prevention and treatment of neurodegenerative disease, Alzheimer's disease, Parkinson's disease, and Amyotrophic lateral sclerosis; medical food for the treatment of spinal cord injury and brain injury; medical food supplements in powdered, liquid and tablet form; medical food supplements in powdered, liquid and tablet form for use in the dietary management of patients with neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, spinal cord injury, and brain injury; ginseng, ginsenocides and omega-3 fatty acids for the dietary management of neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, spinal cord injury, and brain injury

Filing History

ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Dec 2, 2014 MAB3
ABANDONMENT - AFTER EX PARTE APPEAL
Nov 25, 2014 ABN3
EXPARTE APPEAL TERMINATED
Nov 25, 2014 EXPT
EXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF
Oct 16, 2014 EXFB
NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Jul 22, 2014 GEA1
ACTION DENYING REQ FOR RECON E-MAILED
Jul 22, 2014 GECD
ACTION CONTINUING FINAL - COMPLETED
Jul 22, 2014 CNCF
DIVISIONAL PROCESSING COMPLETE
Jul 15, 2014 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 15, 2014 AITU
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jul 14, 2014 JURT
EX PARTE APPEAL-INSTITUTED
Jul 14, 2014 EXPI
EXPARTE APPEAL RECEIVED AT TTAB
Jul 14, 2014 EXAF
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 11, 2014 TEME
DIVISIONAL REQUEST RECEIVED
Jul 10, 2014 DRRR
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 10, 2014 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 10, 2014 ERFR
TEAS REQUEST TO DIVIDE RECEIVED
Jul 10, 2014 ERTD
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 14, 2014 GNFN
FINAL REFUSAL E-MAILED
Jan 14, 2014 GNFR
FINAL REFUSAL WRITTEN
Jan 14, 2014 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 24, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 23, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 23, 2013 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 24, 2013 GNRN
NON-FINAL ACTION E-MAILED
Jun 24, 2013 GNRT
NON-FINAL ACTION WRITTEN
Jun 24, 2013 CNRT
ASSIGNED TO EXAMINER
Jun 20, 2013 DOCK
NOTICE OF PSEUDO MARK E-MAILED
Mar 16, 2013 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2013 NWOS
NEW APPLICATION ENTERED
Mar 14, 2013 NWAP